| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, California, USA; and
Mayo Clinic College of Medicine, Biochemistry & Molecular Biology, Rochester, Minnesota, USA
1Correspondence: LA BioMed, 1124 West Carson St., Torrance, CA 90502, USA. E-mail: rhirschberg{at}labiomed.org
Transforming growth factor-ß (TGF-ß) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-ß receptor. In the current study we show that in cultured NRK49F-renal fibroblasts (but not in tubular or mesangial cells) TGF-ß similarly activates PAK2 as well as c-abl and induces cell proliferation. Inhibition of the c-abl kinase with imatinib mesylate prevents increased proliferation after TGF-ß addition without affecting PAK2. These in vitro findings were extended to rats with unilateral obstructive nephropathy, a disease model of TGF-ß-driven renal fibrogenesis. In obstructed kidneys, PAK2 and c-abl activity were increased but only c-abl activation was blocked by imatinib. Treatment with imatinib did not prevent renal interstitial infiltration of macrophages or phosphorylation and nuclear translocation of smad2/3 in obstructed kidneys. In contrast, imatinib substantially inhibited an increase in the number of interstitial fibroblasts and myofibroblasts and reduced the expression and interstitial accumulation of collagen type III, collagen type IV and fibronectin. These findings indicate that TGF-ß-induced activation of the nonreceptor c-abl tyrosine kinase regulates fibroblast proliferation and, by this means, is a costimulatory signal in TGF-ß-dependent renal fibrogenesis. Inhibition of c-abl activity with imatinib mesylate ameliorates experimental renal fibrosis in rats.—Wang, S., Wilkes, M. C., Leof, L. B., Hirschberg, R. Imatinib mesylate blocks a non-Smad TGF-ß pathway and reduces renal fibrogenesis in vivo.
Key Words: ECM • renal interstitial fibrosis • unilaterial ureteral obstruction • experimental renal fibrosis
This article has been cited by other articles:
|
|
 |
|
  L. van Steensel, D. Paridaens, B. Schrijver, G. M. Dingjan, P. L. A. van Daele, P. M. van Hagen, W. A. van den Bosch, H. A. Drexhage, H. Hooijkaas, and W. A. Dik Imatinib Mesylate and AMN107 Inhibit PDGF-Signaling in Orbital Fibroblasts: A Potential Treatment for Graves' Ophthalmopathy Invest. Ophthalmol. Vis. Sci., July 1, 2009; 50(7): 3091 - 3098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, R. J. Kelm Jr., and A. R. Strauch Transforming Growth Factor {beta}1-mediated Activation of the Smooth Muscle {alpha}-Actin Gene in Human Pulmonary Myofibroblasts Is Inhibited by Tumor Necrosis Factor-{alpha} via Mitogen-activated Protein Kinase Kinase 1-dependent Induction of the Egr-1 Transcriptional Repressor Mol. Biol. Cell, April 15, 2009; 20(8): 2174 - 2185. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Rahimi, M. Andrianifahanana, M. C. Wilkes, M. Edens, T. J. Kottom, J. Blenis, and E. B. Leof Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-{beta} Cancer Res., January 1, 2009; 69(1): 84 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iyoda, K. L. Hudkins, S. Becker-Herman, T. A. Wietecha, M. C. Banas, S. Guo, A. Meyer-Bahlburg, J. Kowalewska, G. Liu, S. F. Ziegler, et al. Imatinib Suppresses Cryoglobulinemia and Secondary Membranoproliferative Glomerulonephritis J. Am. Soc. Nephrol., January 1, 2009; 20(1): 68 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. W. Distler and O. Distler Imatinib as a novel therapeutic approach for fibrotic disorders Rheumatology, January 1, 2009; 48(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Akhmetshina, C. Dees, M. Pileckyte, B. Maurer, R. Axmann, A. Jungel, J. Zwerina, S. Gay, G. Schett, O. Distler, et al. Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J, July 1, 2008; 22(7): 2214 - 2222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Leipner, K. Grun, A. Muller, E. Buchdunger, L. Borsi, H. Kosmehl, A. Berndt, T. Janik, A. Uecker, M. Kiehntopf, et al. Imatinib mesylate attenuates fibrosis in coxsackievirus b3-induced chronic myocarditis Cardiovasc Res, July 1, 2008; 79(1): 118 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Gioni, T. Karampinas, G. Voutsinas, A. E. Roussidis, S. Papadopoulos, N. K. Karamanos, and D. Kletsas Imatinib Mesylate Inhibits Proliferation and Exerts an Antifibrotic Effect in Human Breast Stroma Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 706 - 714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Sfikakis, V. G. Gorgoulis, C. G. Katsiari, K. Evangelou, C. Kostopoulos, and C. M. Black Imatinib for the treatment of refractory, diffuse systemic sclerosis Rheumatology, May 1, 2008; 47(5): 735 - 737. [Full Text] [PDF]
|
|
|
|
 |
|
 G. S. Horan, S. Wood, V. Ona, D. J. Li, M. E. Lukashev, P. H. Weinreb, K. J. Simon, K. Hahm, N. E. Allaire, N. J. Rinaldi, et al. Partial Inhibition of Integrin {alpha}v 6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 56 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Floege, F. Eitner, and C. E. Alpers A New Look at Platelet-Derived Growth Factor in Renal Disease J. Am. Soc. Nephrol., January 1, 2008; 19(1): 12 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Azuma, Y. Nishioka, Y. Aono, M. Inayama, H. Makino, J. Kishi, M. Shono, K. Kinoshita, H. Uehara, F. Ogushi, et al. Role of {alpha}1-Acid Glycoprotein in Therapeutic Antifibrotic Effects of Imatinib with Macrolides in Mice Am. J. Respir. Crit. Care Med., December 15, 2007; 176(12): 1243 - 1250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Gonzalo, L. Beljaars, M. van de Bovenkamp, K. Temming, A.-M. van Loenen, C. Reker-Smit, D. K. F. Meijer, M. Lacombe, F. Opdam, G. Keri, et al. Local Inhibition of Liver Fibrosis by Specific Delivery of a Platelet-Derived Growth Factor Kinase Inhibitor to Hepatic Stellate Cells J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 856 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boor, A. Konieczny, L. Villa, U. Kunter, C. R.C. van Roeyen, W. J. LaRochelle, G. Smithson, S. Arrol, T. Ostendorf, and J. Floege PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1323 - 1331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bujak and N. G. Frangogiannis The role of TGF-{beta} signaling in myocardial infarction and cardiac remodeling Cardiovasc Res, May 1, 2007; 74(2): 184 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Vittal, H. Zhang, M. K. Han, B. B. Moore, J. C. Horowitz, and V. J. Thannickal Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 35 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. Rajkumar, X. Shiwen, M. Bostrom, P. Leoni, J. Muddle, M. Ivarsson, B. Gerdin, C. P. Denton, G. Bou-Gharios, C. M. Black, et al. Platelet-Derived Growth Factor-{beta} Receptor Activation Is Essential for Fibroblast and Pericyte Recruitment during Cutaneous Wound Healing Am. J. Pathol., December 1, 2006; 169(6): 2254 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Wilkes and E. B. Leof Transforming Growth Factor beta Activation of c-Abl Is Independent of Receptor Internalization and Regulated by Phosphatidylinositol 3-Kinase and PAK2 in Mesenchymal Cultures J. Biol. Chem., September 22, 2006; 281(38): 27846 - 27854. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-C. Yang, S. Chen, T. Clegg, X. Li, T. Morgan, S. A. Estwick, J. Yuan, W. Khalaf, S. Burgin, J. Travers, et al. Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-{beta} signaling Hum. Mol. Genet., August 15, 2006; 15(16): 2421 - 2437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. C. Henderson, A. C. Mackinnon, S. L. Farnworth, F. Poirier, F. P. Russo, J. P. Iredale, C. Haslett, K. J. Simpson, and T. Sethi Galectin-3 regulates myofibroblast activation and hepatic fibrosis PNAS, March 28, 2006; 103(13): 5060 - 5065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Hirschberg What Benjamin Babington, William Osler, Frederick Weber, and Henri Rendu did not know Cardiovasc Res, November 1, 2005; 68(2): 180 - 182. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Moustakas and C.-H. Heldin Non-Smad TGF-{beta} signals J. Cell Sci., August 15, 2005; 118(16): 3573 - 3584. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
